OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug
Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.